<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282682</url>
  </required_header>
  <id_info>
    <org_study_id>FSPORT-CU-ADAM</org_study_id>
    <nct_id>NCT03282682</nct_id>
  </id_info>
  <brief_title>Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male</brief_title>
  <official_title>Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male (ADAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Comenius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian School of Sport Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slovak Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Comenius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of 12-week strength training program with and without
      testosterone replacement therapy (TRT) on body composition, physical function, selected
      biochemical markers of metabolic health, molecular parameters of training adaptation and the
      quality of life patients with ADAM. The investigators believe, that strength training program
      performed 2 times per week for 12 weeks can improve body composition (decrease fat mass and
      gain lean mass), muscle strength, muscle power and general quality of life in all training
      groups. In addition, combination TRT and strength training could help decrease fat mass,
      improve BMI, cardio-respiratory fitness and thus provide optimal therapy combination for
      hypogonadal ageing males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is 3 groups controlled 12-week study to assess the effect of testosterone
      replacement therapy (TRT) with strength training (ST) and strength training (ST) for
      hypogonadal participants without testosterone replacement therapy (NON-TRT) with control
      healthy eugonadal group, that is also engaged in strength training.

      Strength training protocol starts one week after all the pre-intervention testing. The
      intervention is performed at the Comenius University in Bratislava, Faculty of Physical
      Education and Sport (FSPORT CU) in Slovakia. The strength training protocol follows a
      modified resistance exercise program. The participants perform strength training sessions two
      times per week for 12 weeks. All training sessions are supervised and guided by professional
      coaches with university degree in sports training to ensure safety, technique and progression
      in training load, with a maximum of three participants per coach.

      Each training session include 5-minute general dynamic warm-up followed by progressive
      strength training with exercises for the entire body. The strength exercises are performed
      with free weights and on machines. The training program consist of 6 exercises for upper and
      lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in
      eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes.
      The participants are instructed to perform concentric action in 2 s and immediately after
      eccentric action in also 2 s. The exercises performed are: leg press, split squats, bench
      press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell
      bench press, incline dumbbell bench press. Training equipment is provided by KOHI Leopoldov,
      Slovakia and Technogym, Italia.

      Clinical and muscle cellular outcomes are collected before the intervention (pre-testing
      assessments) and after the intervention (post-testing assessments). Post intervention
      measurements start 7 days after intervention and go up to 3 weeks after intervention.

      Clinical outcomes Body composition analysis is measured by Dual-energy X-ray Absorptiometry
      using Hologic fan-beam bone densitometer Discovery QDR series. LBM(lean body mass) is
      measured in total body and separately for arms, legs and trunk. The changes in lower and
      upper body LBM are investigated separately because of differences in androgen sensitivity in
      leg muscles compared to neck, chest and shoulder muscles. Body weight is measured by
      bioimpedance scale, the height by stadiometer and waist circumference by tape. The body mass
      index is calculated.

      Biochemical outcomes Fasting morning venous blood is taken from 8:00 am to 10:00 am. The
      haematological and biochemical parameters analysed are Haemoglobin, hematocrits, leucocytes,
      thrombocytes, glucose, urea, sodium, potassium, calcium, ALAT, total cholesterol, LDL
      cholesterol, HDL cholesterol, triglyceride, testosterone, oestrogen, LH, FSH, SHBG, albumin,
      bilirubin, total protein, CRP, insulin, PSA.

      Physical functioning Muscle strength is measured by novel portable isometric knee dynamometer
      (maximal voluntary contraction of isometric knee extension, isometric knee flexion), hand
      grip strength dynamometry by Camry Digital Hand Dynamometer, predicted 1RM leg press from
      multiple repetition maximum testing. Cardio-respiratory fitness is measured by The Single
      Stage Treadmill Walking Test on Woodway Pro Treadmill, 10-m fast walk and 10-m usual walk
      measured by Photocells.

      Quality of life The general health status is measured by The Short Form (36) Health Survey
      patient-reported survey of patient health (SF-36). In addition to that clinically
      investigating the health-related quality of life (HRQoL) and symptoms of aging men are
      measured by Aging Males' Symptom Scale (AMS).

      Muscle cellular outcomes Muscle biopsies are obtain from approximately 80% of the subjects
      included in the study. Participants not willing to undergo biopsy are still eligible for
      trial participation.

      With the participant in a supine position, a 5 mm Muscle Biopsy Cannula (Bergstrom-stille,
      Sweden) with manual suction is used to obtain muscle samples (200 mg), under local
      anaesthesia (Lidocain 2%,). Before the intervention the biopsy is obtained from the
      mid-section of the right musculus vastus lateralis, and after the intervention the biopsy is
      obtained 3 cm proximal to the pre-intervention biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is 3 arms 12-week strength training program to assess the effect of testosterone replacement therapy (TRT) with strength training (ST) and strength training (ST) for hypogonadal patients without testosterone replacement therapy (NON-TRT) with control healthy eugonadal group, that is also engaged in strength training.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body composition - Change in Lean Mass at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Separately in arms, legs, trunk and total body by Dual-energy X-ray Absorptiometry using Hologic fan-beam bone densitometer Discovery QDR series.Measured in g/m2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition - Change in Fat Mass at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Separately in arms, legs, trunk and total body by Dual-energy X-ray Absorptiometry using Hologic fan-beam bone densitometer Discovery QDR series.Measured in g/m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition - Change in Total Body Mass at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Separately in arms, legs, trunk and total body by Dual-energy X-ray Absorptiometry using Hologic fan-beam bone densitometer Discovery QDR series.Measured in g/m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 10-m Usual Walk Test at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measured in seconds by Microgates Photocells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 10-m Fast Walk Test at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measured in seconds by Microgates Photocells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Handgrip strength at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measured in kg by Camry Digital Hand Dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal voluntary contraction (MVC) of isometric knee extension at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measured in Nm by Novel Portable Isometric Knee Dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal voluntary contraction (MVC) of isometric knee flexion at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measured in Nm by Novel Portable Isometric Knee Dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in The Single Stage Treadmill Walking Test at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>This test is focused on calculated VO2max in ml.kg-1.min-1 from speed measured on Woodway Pro Treadmill.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in predicted one repetition maximum on Leg press at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>One repetition maximum(1RM) in kg on leg press is predicted from multiple repetition maximum testing and measured on Life Fitness Signature Series Leg Press machine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal voluntary contraction (MVC) in benchpress at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measured in N by FiTRO Force Plates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in The Short Form (36) Health Survey (SF36) at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Patient-reported survey of patient health (SF-36), clinically investigating the health-related quality of life (HRQoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aging Males' Symptom (AMS) Scale at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>Measuring symptoms of ageing men by numeric score scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical parameters at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 7-10 days after intervention</time_frame>
    <description>The haematological and biochemical parameters analysed are haemoglobin(g/l), hematocrits(ratio), leucocytes (10^9/l), thrombocytes (10^9/l), glucose (mmol/l), urea (mmol/l), sodium (mmol/l), potassium (mmol/l), calcium (mmol/l), ALAT, total cholesterol (mmol/l), LDL cholesterol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l), testosterone (nmol/l), oestrogen (nmol/l), LH (nmol/l), FSH (nmol/l), SHBG (nmol/l), albumin (g/l), bilirubin (Âµmol/l), total protein (g/l), CRP(mg/l), insulin (mIU/l), PSA (ug/l).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle biopsy - Change in muscle fiber size at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 10-14 days after intervention</time_frame>
    <description>Muscle fiber size measured in um2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle biopsy - Change in regulators of muscle fiber size at 12 weeks</measure>
    <time_frame>7-14 days before intervention, 10-14 days after intervention</time_frame>
    <description>Regulators of muscle fiber size - number of myonuclei per muscle fiber, number of satellite cells per muscle fiber, number of satellite cells and myonuclei positive for androgen receptors, proteins involved in muscle hypertrophy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hypogonadism, Male</condition>
  <condition>Physical Activity</condition>
  <condition>Testosterone Deficiency</condition>
  <arm_group>
    <arm_group_label>hypogonadal males without TRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Strength training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypogonadal males with TRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Strength training and regular prescribed testosterone therapy given by participant urologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy eugonadal males</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Strength training</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Strength training</intervention_name>
    <description>The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.</description>
    <arm_group_label>hypogonadal males without TRT</arm_group_label>
    <arm_group_label>hypogonadal males with TRT</arm_group_label>
    <arm_group_label>healthy eugonadal males</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of secondary hypogonadism on testosterone replacement therapy, newly
             diagnosed patients of secondary hypogonadism.

        Exclusion Criteria:

          -  Regular strength training, medical treating osteoporosis, abnormal digital rectal
             results, conditions which are medical contraindications (without adjusting state):
             diabetes mellitus, severe cardiac arrhythmia, uncontrolled hypertension, unstable
             angina pectoris, chronic obstructive pulmonary disease, epilepsy, unstable bone
             lesions with high risk of fracture, prostate cancer or abnormal serum PSA levels
             without adverse histological examination.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Sedliak, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comenius University of Bratislava, Faculty Physical Education and Sport</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Kralik, Magister</last_name>
    <phone>+421 910272863</phone>
    <email>michal.kralik@uniba.sk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Comenius University in Bratislava, Faculty of physical education and sport</name>
      <address>
        <city>Bratislava</city>
        <zip>814 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Kralik</last_name>
      <phone>+421 910272863</phone>
      <email>michal.kralik@uniba.sk</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <results_reference>
    <citation>Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008 Sep-Oct;29(5):534-9. doi: 10.2164/jandrol.108.005454. Epub 2008 Jun 20. Review.</citation>
    <PMID>18567642</PMID>
  </results_reference>
  <results_reference>
    <citation>Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T, Wolfe P, Kohrt WM, Ruscin JM, Kittelson J, Cress ME, Ballard R, Schwartz RS. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab. 2013 May;98(5):1891-900. doi: 10.1210/jc.2012-3695. Epub 2013 Mar 26.</citation>
    <PMID>23533227</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarz ER, Willix RD Jr. Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men. J Geriatr Cardiol. 2011 Dec;8(4):201-6. doi: 10.3724/SP.J.1263.2011.00201.</citation>
    <PMID>22783306</PMID>
  </results_reference>
  <results_reference>
    <citation>Kadi F, Bonnerud P, Eriksson A, Thornell LE. The expression of androgen receptors in human neck and limb muscles: effects of training and self-administration of androgenic-anabolic steroids. Histochem Cell Biol. 2000 Jan;113(1):25-9.</citation>
    <PMID>10664066</PMID>
  </results_reference>
  <results_reference>
    <citation>Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523. Epub 2013 Dec 16. Review.</citation>
    <PMID>24344218</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Comenius University</investigator_affiliation>
    <investigator_full_name>Milan Sedliak</investigator_full_name>
    <investigator_title>Independent researcher, Vice-dean for science, research and international cooperation</investigator_title>
  </responsible_party>
  <keyword>hypogonadism</keyword>
  <keyword>aging male</keyword>
  <keyword>strength training</keyword>
  <keyword>physical activity</keyword>
  <keyword>testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

